3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025 By Investing.com
Investing.com – Bernstein analysts are optimistic about Europe’s pharmaceutical sector as it heads into 2025, despite concerns about policy changes and market resistance. The firm identified three main reasons for the positive outlook in this week’s note Solid growth prospects: Bernstein forecasts 8% EPS compound annual growth rate (CAGR) from 2025 to 2030, excluding Novo … Read more